522

 

WHAT:  Design, Tracking, Oversight, Review of studies mandated under section 522, Federal Food, Drug and Cosmetic Act

WHY: To ensure well-designed 522 postmarket surveillance studies, conducted effectively and efficiently in the least burdensome manner

WHEN: Since 2008

WHO: Division of Epidemiology , Office of Surveillance and Biometrics, CDRH

HOW: CDRH Internal Tracking System, PUBLIC WEBPAGE

LINK


Leave a Reply


Fill in your details below or click an icon to log in:

WordPress.com Logo



You are commenting using your WordPress.com account.
Log Out / 
Change )

Google photo



You are commenting using your Google account.
Log Out / 
Change )

Twitter picture



You are commenting using your Twitter account.
Log Out / 
Change )

Facebook photo



You are commenting using your Facebook account.
Log Out / 
Change )

Connecting to %s